Jupiter Topco LLC Invests $450.14 Million in United Therapeutics Corporation $UTHR

Key Points

• Jupiter Topco LLC acquired 831,129 shares of United Therapeutics in the second quarter, worth approximately $450.14 million and representing about 1.94% of the company.
• United Therapeutics reported quarterly EPS of $7.27, exceeding the $6.86 consensus estimate, although revenue of $783.3 million fell short of expectations and declined 1.9% year over year.
• Analysts maintain a generally positive view, with 11 Buy ratings and two Holds, producing a “Moderate Buy” consensus and an average price target of $646 versus the reported share price of $518.53.

Jupiter Topco LLC bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 831,129 shares of the biotechnology company's stock, valued at approximately $450,140,000. Jupiter Topco LLC owned approximately 1.94% of United Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the stock. Torren Management LLC purchased a new stake in shares of United Therapeutics during the 4th quarter valued at about $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after buying an additional 56 shares during the period. Fiduciary Financial Advisors bought a new stake in United Therapeutics during the 2nd quarter worth approximately $30,000. WealthCollab LLC boosted its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares during the period. Finally, Rakuten Securities Inc. lifted its position in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 46 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Trading Up 1.1%

Shares of NASDAQ:UTHR opened at $518.53 on Wednesday. United Therapeutics Corporation has a twelve month low of $302.19 and a twelve month high of $609.35. The company has a market cap of $22.24 billion, a PE ratio of 18.55, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59. The company's 50 day moving average is $531.75 and its 200 day moving average is $538.30.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm's quarterly revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the firm posted $6.41 earnings per share. Equities research analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Analyst Ratings Changes

UTHR has been the subject of a number of research analyst reports. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd. Bank of America reduced their price objective on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Weiss Ratings upgraded United Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, August 13th. Wells Fargo & Company raised shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada cut their target price on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $646.00.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the company's stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $545.83, for a total value of $5,185,385.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company's stock, valued at approximately $22,113,210.79. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company's stock, valued at approximately $10,311,581.28. This trade represents a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 434,075 shares of company stock valued at $233,340,010 in the last three months. Insiders own 8.60% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source